This paper describes work to develop a novel human antibody nasal spray as a prophylactic treatment against SARS-CoV-2. Formulations were developed at two protein concentrations and assessed for delivery using an Aptar VP3 nasal spray pump. Both formulations were shown to be suitable for nasal delivery in terms of pH, osmolality, and delivered droplet size; no evidence of protein agglomeration was observed as a result of spraying. Further studies are planned to investigate the stability of the developed products and to establish pharmacokinetics and pharmacodynamics.
Learn more about Aptar Pharma Expertise
in Nasal Drug Delivery
This Might Also Be of Interest
A track record of success for nasal drug delivery in drug repurposing
Publications, Pharmaceutical, Innovation & Insights, Device Innovations, Brand Differentiation, Product Solutions
The Nasal Drug Delivery Journey: from Systemic to Nose-to-Brain?
Webinars, Pharmaceutical, Innovation & Insights, Device Innovations, Market Insights, Product Solutions
Using multi-dose nasal spray pumps for intranasal drug delivery
Publications, Pharmaceutical, Product Solutions, Innovation & Insights, Device Innovations
